



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections



Letícia Aparecida Schiave^a, Erika Nascimento^{a,*}, Fernando Crivelenti Vilar^a,
Tissiana Marques de Haes^b, Osvaldo Massaiti Takayanagui^b,
Cristiane Masetto de Gaitani^c, Roberto Martinez^a

^a Universidade de São Paulo (USP), Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica, Ribeirão Preto, SP, Brazil

^b Universidade de São Paulo (USP), Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Ribeirão Preto, SP, Brazil

^c Universidade de São Paulo (USP), Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Ribeirão Preto, SP, Brazil

ARTICLE INFO

Article history:

Received 21 July 2017

Accepted 20 October 2017

Available online 13 November 2017

Keywords:

Fluconazole

Cryptococcosis

Cerebrospinal fluid

ABSTRACT

Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of *Cryptococcus* spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the *Cryptococcus* spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting *Cryptococcus* spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400–800 mg.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Fluconazole is extensively used as a systemic antifungal agent because of its favorable pharmacological characteristics such

as low toxicity, good bioavailability and appropriate levels in blood and in infected tissues, including the central nervous system (CNS). In addition, fluconazole acts against various agents that induce endemic and opportunistic mycoses, with emphasis on its clinical use for the treatment of *Candida* spp. and *Cryptococcus* spp. infections.^{1,2}

Together with amphotericin B and 5-flucytosine, fluconazole is a component of the therapeutic regimen currently

* Corresponding author.

E-mail address: erika.nascimento@gmail.com (E. Nascimento).

<https://doi.org/10.1016/j.bjid.2017.10.003>

1413-8670/© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

recommended for the control of neurocryptococcosis, particularly during treatment consolidation and maintenance phases.³ However, some cases are refractory to antifungal therapy and early or late deaths may occur in more than 30% of all patients.^{4,5} Poor response to treatment has been related to more extensive dissemination of the infection and to host factors.⁶ However, treatment failure may also be due to insufficient antifungal dosage and tissue level or to the lack of *Cryptococcus* spp. susceptibility to fluconazole.⁷

Early studies have shown that fluconazole reaches sufficient levels in cerebrospinal fluid (CSF) for the treatment of fungal infections in the CNS.⁸ In contrast to controlled studies, in current clinical practice the patients receive fluconazole of various origins and the clinical conditions may differ from those standardized in studies with the original drug. Scarce data about generic antifungals motivated a comparison between innovator fluconazole and similar drugs in an experimental model.⁹ For the same reason, in this study fluconazole levels were reevaluated in blood and CSF of patients under treatment for cryptococcosis and other fungal infections.

Materials and methods

Fifteen adult patients were included at random in the present study while receiving fluconazole treatment between September 2012 and May 2014 at the University Hospital of the Ribeirão Preto Medical School, University of São Paulo, Brazil. All but one of these patients were HIV-infected and fluconazole was being used to treat neurocryptococcosis ($n=13$), histoplasmosis ($n=1$) or candidiasis ($n=1$). Neurocryptococcosis cases were preferably included because of periodic CSF sampling and the use of different fluconazole dosages during treatment, permitting the comparison of the levels of this drug according to daily dose received. *Cryptococcus* spp. was isolated in Sabouraud agar to which the CSF was added and identified by standard medical mycology methods. This identification was confirmed by Vitek 2 automated system (Biomérieux, France). Histoplasmosis was diagnosed by histopathological examination and a positive serology for *Histoplasma capsulatum* antibodies. Oral candidiasis was diagnosed by oral examination of an AIDS patient. The following brands of fluconazole were administered to the patients: generic Fluconazol (Sanobiol, Brazil) for intravenous infusion; capsules for oral use – Fluxilase[®], (Laboris, Brazil) or Flucazol[®] (Cristália, Brazil). The patients received fluconazole doses of 200–800 mg/day intravenously ($n=4$), orally ($n=5$) or by intravenous route followed by oral route ($n=6$). Nine patients were included in the study more than once, five of them for receiving a different daily dose and/or for using another route of administration. Amphotericin B and antiretrovirals were used simultaneously to fluconazole in 8/13 and 10/13 patients with cryptococcosis, respectively. Among antiretroviral drugs, all 10 patients used lamivudine, and other accompanying drugs of the regimen were combinations of tenofovir or zidovudine with efavirenz or lopinavir/ritonavir.

Blood and CSF samples were collected between 24 h and 80 days after the beginning fluconazole treatment. CSF was sampled only when requested by medical staff for

laboratory control of cryptococcosis treatment. Drug levels were measured in blood samples collected one or two hours after administering a fluconazole dose. CSF was collected by lumbar puncture three to four hours after ingestion or infusion of a fluconazole dose. Fluconazole levels were measured in two to seven blood samples per patient for a total of 53 samples, and in one to four CSF samples for a total of 22 samples. The correlation between serum and CSF concentrations of the drug was determined in 10 patients from whom 15 sample pairs were collected on the same day.

Fluconazole levels were measured by high performance liquid chromatography (HPLC).¹⁰ Fluconazole was extracted from serum and CSF by liquid–liquid extraction using ethyl acetate as an organic solvent. HPLC was carried out using a Shimadzu chromatograph (Shimadzu Corporation, Kyoto, Japan), with a Supelco Analytical Ascentis 4.6 mm × 25 cm C18[®] column with 5 μm particles, an Ascentis C18 Supelguard[®] guard column (4 mm × 2 cm, with 5 μm particles) and a mobile phase consisting of 10 mM sodium phosphate buffer, pH 5.7, and acetonitrile (75:25, v/v) (Merck Darmstadt, Germany), at a flow rate of 1 mL/min, with detection at 210 nm. The HPLC method was validated for fluconazole (Sigma–Aldrich, USA) quantification in serum and CSF. In the range of 0.5–62.5 μg/mL fluconazole concentration, the correlation coefficients were 1.0000 and 0.9998 for serum and CSF, respectively. The precision expressed as variation coefficient percentage ranged 0.5–8.1 for serum and 0.7–4.5 for CSF in intra-run and inter-run analysis. *Cryptococcus* spp. susceptibility to fluconazole was determined in isolates from 11 patients by broth microdilution method as proposed by the Clinical Laboratory Standards Institute.¹¹

Fluconazole levels were analyzed according to neurocryptococcosis patients' outcome after one year of diagnosis. Two groups of patients were compared: survivors – 9/13 cases vs. deaths plus one case of refractory cryptococcosis – 4/13 cases. In the survival group the median age was 43 years (range: 21–63), 8/9 were men and 5/9 and 6/9 were also receiving amphotericin B and antiretrovirals, respectively. Five patients were in the consolidation phase of antifungal therapy and four of them had been previously treated with amphotericin B. In the death/refractory group the median age was 49 years (range: 32–65), all were men and 3/4 and 2/4 were also receiving amphotericin B and antiretrovirals, respectively. One patient was in the consolidation phase of treatment and had received amphotericin B previously.

The Mann–Whitney test was used to compare blood and CSF fluconazole levels according to the daily dose of the drug received by the patients, with the level of significance set at $p < 0.05$. The correlation between blood and CSF levels of the drug was determined using Excel[®] software (Microsoft Corporation). The study was approved by the Research Ethics Committee of the University Hospital, Ribeirão Preto Medical School (protocol no. 4096/2012) and all patients gave written informed consent to participate.

Results

Table 1 shows that the median serum levels of fluconazole increased with increasing daily doses of the drug, reaching

Table 1 – Serum and cerebrospinal fluid (CSF) fluconazole levels according to daily dose administered to 15 patients.

Dose	200 mg/day	400 mg/day	600 mg/day	800 mg/day
Serum levels ($\mu\text{g/mL}$)				
N° samples	4	15	14	20
Median	20.2a	27.7b	33.8c	34.9d
Range	7.5–33.4	8.5–42.1	26.9–50.1	17.0–60.5
CSF levels ($\mu\text{g/mL}$)				
N° samples	2	3	8	8
Median	10.5e	32.5f	28.7g	23.3h
Range	6.2–14.7	26.8–42.3	20.9–60.3	7.3–39.7

Significant differences by the Mann Whitney test: b vs. c – $p < 0.05$; b vs. d – $p < 0.01$; e vs. f – $p < 0.05$; e vs. g – $p < 0.05$; e vs. h – $p < 0.05$

Table 2 – Serum and CSF fluconazole levels ($\mu\text{g/mL}$) in cryptococcal meningitis cases and minimum inhibitory concentration (MIC) of fluconazole for *Cryptococcus* spp. isolates according to outcome of the patients.

Patient	MIC($\mu\text{g/mL}$)	Serum level-median(Range) (N° samples)	CSF ^a level-median(Range) (N° samples)	Fluconazole dose-g/d(Route)
Survival (n=9)				
1	(ND) ^b	26.2 (25.4–26.9)(3)	17.0 (17.0–17.0)(1)	800 (IV)
2	0.5	40.4 (35.7–44.5)(5)	39.7 (37.0–42.3)(2)	400–800 (PO)
5	1.0	34.5 (23.1–40.6)(4)	26.4 (25.2–27.5)(2)	800(IV)–600 (PO)
7	0.5	33.0 (29.7–35.9)(3)	(ND)	400 (PO)
8	1.0	28.6 (27.2–30.0)(2)	26.1 (25.3–26.8)(2)	400–600 (PO)
11	0.5	34.7 (32.3–37.1)(2)	14.7 (14.7–14.7)(1)	200 (PO)
13	1.0	33.7 (27.4–39.9)(4)	11.1 (7.3–14.8)(2)	800 (PO)
14	2.0	33.8 (32.1–36.4)(4)	13.8 (6.2–21.4)(2)	200–800 (PO)
15	(ND)	28.3 (27.5–29.1)(2)	19.1 (17.2–20.9)(2)	600 (PO)
Median	1.0	33.7 (26.2–40.4)	18.1 (11.1–39.7)	
Refractory and death (n=4)				
3	0.5	32.7 (29.5–36.0)(4)	32.5 (22.7–42.4)(3)	400(OR)–600(IV)
4	0.25	51.2 (50.1–60.5)(4)	50.0 (39.7–60.3)(2)	600–800 (IV)
6	0.13	27.7 (25.9–29.3)(3)	29.8 (29.8–29.8)(1)	600 (IV)
9	0.25	28.1 (26.3–31.1)(4)	28.8 (27.4–30.2)(2)	600–800(PO)
Median	0.25	30.4 (27.7–51.2)	31.2 (28.8–50.0)	

^a Cerebrospinal fluid.

^b Not done

IV, intravenous; PO, oral route.

a significant difference between the daily dose of 600 or 800 mg/d and the dose of 400 mg/d. The lowest median serum level was observed at the dose of 200 mg/d, although the small number of samples prevented reaching significance compared to the higher levels provided by daily doses between 400 and 800 mg.

In the CSF, the median levels of fluconazole were similar with daily doses between 400 and 800 mg/d, but exceeded the levels obtained with 200 mg/d. A good correlation between serum and CSF levels was detected in 15 blood-CSF pairs in patients receiving daily doses between 400 and 800 mg (Fig. 1).

Cryptococcus isolated from the patients showed susceptibility to fluconazole, as demonstrated by a MIC between 0.125 and 2.0 $\mu\text{g/mL}$, MIC 50 = 0.5 $\mu\text{g/mL}$ and MIC 90 = 2.0 $\mu\text{g/mL}$.

No differences were verified in MIC distribution and of serum fluconazole levels in patients with cryptococcosis who survived compared to those with a non-favorable outcome. CSF drug levels of the death/refractory group were higher than levels of the survival group (Table 2).

Discussion

The most relevant result of the present study was that fluconazole concentrations reached in blood and CSF are sufficient




Fig. 1 – Correlation between serum and cerebrospinal fluid fluconazole levels in 10 patients (15 pairs of samples) with cryptococcal meningitis and AIDS.

to inhibit *Cryptococcus* spp. isolated from the patients of this series. Fluconazole doses higher than 200 mg/d led to higher levels in CSF, which were safer regarding their antifungal action in cases of meningeal cryptococcosis.

The pharmacokinetics of fluconazole is linear and dose-dependent, and higher daily doses of the drug have

been shown to result in longer survival of patients with candidiasis.¹² The better pharmacokinetics parameter associated with fluconazole efficacy is the area under the curve of fluconazole blood concentration (AUC) divided by MIC (AUC/MIC) which must be ≥ 100 for *Candida* species.¹³ AUC near 386/L/h can be obtained with 400 mg/day of fluconazole and this dose is sufficient to control 99% of *Candida* spp. infections whose MIC is $\leq 2 \mu\text{g/mL}$.¹⁴ In respect to cryptococcosis, it is more complicated to define pharmacokinetic parameters for better outcomes because of several factors including a commonly meningeal infection and a non-rare cerebral involvement. An experimental study with four *Cryptococcus* isolates estimated fluconazole mean AUC/MIC = 389 for a fungistatic effect.¹⁵ In a murine model of cryptococcosis, fluconazole cerebral levels were lower than blood levels which could be lower than the MIC for *Cryptococcus* spp.^{15,16} Fluconazole doses and respective blood and CSF levels have been associated with neurocryptococcosis cases outcome. A dose ≥ 1200 mg/day was recommended if this triazole is employed in monotherapy.³

The serum levels of fluconazole measured in the present study are comparable to those reported in other studies using daily doses of 200–400 mg^{13,17} or of 800 mg.^{18,19} In patients with cryptococcosis treated with daily doses of 800 and 1000 mg/day the mean levels of serum fluconazole were 37.0 $\mu\text{g/mL}$ and 42.5 $\mu\text{g/mL}$,²⁰ respectively. A mean trough serum concentration of 5.6 (range: 0.11–18.0) $\mu\text{g/mL}$ was verified in hematologic patients using 200 mg/day of this triazole.²¹ There was no significant difference between the levels obtained when the drug was administered by oral or intravenous route (data not shown).

The levels of fluconazole detected here in the CSF were close to those observed in other studies on patients with cryptococcosis and HIV co-infection, whose mean CSF levels of the drug reached 25.1 $\mu\text{g/mL}$, 32.7 $\mu\text{g/mL}$, and 36.3 $\mu\text{g/mL}$ with daily doses of 400 mg, 800 mg, and 1000 mg, respectively.^{19,20} The levels of fluconazole in the CSF and in blood showed a good correlation, in agreement with the concept that this drug has similar concentrations in the two fluids.²² Blood and CSF fluconazole concentrations observed in this study are apparently not related to the bad outcome of some patients.

All *Cryptococcus* spp. isolates were susceptible to fluconazole based on the epidemiological cut-off estimated at 8 $\mu\text{g/mL}$.²³ Resistance or non-susceptibility of *Cryptococcus* spp. to fluconazole may be the reason for treatment failure in cryptococcosis, especially if only this antifungal agent is used for treatment.² Refractory/relapsing cryptococcal infection has been associated with *Cryptococcus neoformans* not being susceptible to fluconazole.²⁴ Fluconazole at the dose of 800 mg/d or alternative treatment with voriconazole was necessary to maintain survival of patients infected with *Cryptococcus* spp. with a MIC above 8 $\mu\text{g/mL}$ for this drug.⁷ A slow or delayed recovery of patients with neurocryptococcosis should indicate a *Cryptococcus* spp. susceptibility test and the monitoring of fluconazole levels in the CSF.^{25,26}

In this study it was not possible to estimate several pharmacokinetic parameters of fluconazole. However, it confirmed that levels of this triazole were directly related to the daily dose received by patients, which must be carefully managed, particularly in neurocryptococcosis cases. Another limitation

of the study refers to the higher percentage of patients already in consolidation phase of treatment in the group of survivors in comparison to the death/refractory cryptococcosis group, impairing the analysis of the fluconazole levels according to outcome. Interaction of fluconazole with other drugs prescribed to meningeal cryptococcosis cases may occur, but amphotericin B and antiretrovirals in particular do not modify fluconazole levels.²⁷

In conclusion, fluconazole reached sufficient blood and CSF levels to act against most *Cryptococcus* spp. that cause meningitis in AIDS patients, even though it was administered under non-standardized clinical conditions and the fluconazole used was not the original brand used to evaluate pharmacokinetics in initial studies. Daily doses of 400 mg or higher provided more appropriate CSF concentrations for treating *Cryptococcus* spp., particularly isolates with lower susceptibility to fluconazole.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

LA Schiave received a scholarship from the São Paulo Research Foundation (FAPESP) related to a research project on the determination of fluconazole levels (grant 2010/51030-4). The Foundation of Support to Teaching, Research and Assistance of Hospital das Clínicas, Ribeirão Preto Medical School (FAEPA) provided financial support for this study. We thank John Carpenter, Ribeirão Preto, SP, Brazil, for the English revision.

REFERENCES

1. Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: a comparative review. *Drugs*. 2011;71:2405–19.
2. Bicanic T, Harrison T, Niepieklo A, Dyakopu W, Meintjes G. Symptomatic relapse of HIV – associated cryptococcal meningitis after initial fluconazole monotherapy. The role of fluconazole resistance and immune reconstitution. *Clin Infect Dis*. 2006;43:1069–73.
3. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50:291–322.
4. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV – associated cryptococcal meningitis: implications for improving outcomes. *Clin Infect Dis*. 2014;58:736–45.
5. Rubio FG, Zanan JR, de Almeida MTG, de Gongora DVN. Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients. *Braz J Infect Dis*. 2007;11:203–7.
6. Nascimento E, Vitali LH, Tonani L, Kress MR, Takayanagui OM, Martinez R. Refractory and/or relapsing cryptococcosis associated with AIDS: clinical features, genotype and virulence factors of *Cryptococcus* spp. isolates. *Am J Trop Med Hyg*. 2016;94:975–81.
7. Nasri H, Kabbani S, Bou Alwan M, et al. Retrospective study of cryptococcal meningitis with elevated minimum inhibitory

- concentration to fluconazole in immunocompromised patients. *Open Forum Infect Dis*. 2016;3, ofw 076.
8. Tucker RM, William PL, Arathoon EG, et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioid meningitis. *Antimicrob Agents Chemother*. 1988;32:369–73.
 9. Gonzalez JM, Rodriguez CA, Zuluaga AF, Agudelo M, Vesga O. Demonstration of therapeutic equivalence of fluconazole generic products in the neutropenic mouse model of disseminated candidiasis. *PLOS ONE*. 2015;10:e0141872.
 10. Misoguchi T, Hirata K, Kobayashi S, Chikuma T. Monitoring of fluconazole in serum of patients undergoing hemodiafiltration by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. *Pharmazie*. 2012;67:765–7.
 11. Clinical and Laboratory Standards Institute (CLSI). M27-A2. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third ed. Wayne, PA, USA: CSLI; 2008.
 12. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. *Antimicrob Agents Chemother*. 2007;51:35–9.
 13. Sinnollareddy MG, Roberts JA, Lipman J, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study. *Crit Care*. 2015;19:33.
 14. Rodríguez-Tudela JL, Almirante B, Rodríguez-Pardo D, et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. *Antimicrob Agents Chemother*. 2007;3599–604.
 15. Sudan A, Livermore J, Howard SJ, et al. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. *Antimicrob Agents Chemother*. 2013;57:2793–800.
 16. Santos JR, César IC, Costa MC, et al. Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis. *Eur J Pharm Sci*. 2016;92:235–43.
 17. Buijk SLCE, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. *Intensive Care Med*. 2001;27:115–21.
 18. Sobue S, Tan K, Layton G, Leclerc V, Weil A. Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. *Br J Clin Pharmacol*. 2004;57:773–84.
 19. Manosuthi W, Chetchotisakd P, Nolen TL, et al. Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV associated cryptococcal meningitis infected patients. *HIV Med*. 2010;11:276–81.
 20. Menichetti F, Fiorio M, Torti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. *Clin Infect Dis*. 1996;22:838–40.
 21. Ceesay MM, Couchman L, Smith M, Wade J, Flanagan RJ, Pagliuca A. Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: trough serum concentrations in relation to outcome. *Med Mycol*. 2016;54:691–8.
 22. Nau R, Sörgel F, Elfert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous infections. *Clin Microbiol Rev*. 2010;23:858–83.
 23. Espinel-Ingroff A, Aller AI, Canton E, et al. *Cryptococcus neoformans* – *Cryptococcus gattii* species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cut off values for fluconazole, itraconazole, posaconazole, and voriconazole. *Antimicrob Ag Chemother*. 2012;56:5898–906.
 24. de Carvalho Santana R, Schiave LA, Dos Santos Quaglio AS, de Gaitani CM, Martinez R. Fluconazole non-susceptible *Cryptococcus neoformans*, relapsing/refractory cryptococcosis and long-term use of liposomal amphotericin B in an AIDS patient. *Mycopathologia*. 2017, <http://dx.doi.org/10.1007/s11046-017-0165-1>.
 25. Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. *Curr Clin Pharmacol*. 2013;8:5–12.
 26. Shoji H, Takuma T, Ohbayashi H, Yoshida K, Yamamoto T, Niki Y. Measurement of antifungal drug levels in cerebrospinal fluid for cryptococcal meningoencephalitis. *J Infect Chemother*. 2012;18:775–9.
 27. Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK. Clinically relevant drug-drug interactions between antiretrovirals and antifungals. *Expert Opin Drug Metab Toxicol*. 2014;10:561–80.